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pants were requested to categorize patients according to initial AF approach, i.e. 
pharmacological or non-pharmacological (interventional) treatment option. Discrete 
sets of answers were provided for each patient group. RESULTS: A pharmacological 
therapy was the initial treatment approach for 89.6% of patients (rhythm control: 
59.5%, rate control: 40.5%), whereas 5.2% had initially undergone non-pharmaco-
logical therapy, mainly catheter ablation (96% of cases). The remaining 5.2% received 
no treatment. Patients on rhythm control were mainly prescribed a Class-III (28.9%), 
Class-Ic (28.9%) or Class-II anti-arrhythmic agent, whereas 13.4% received a combi-
nation. In the rate control group, the treatments of choice were b-blockers (37.0%) 
and digoxin (24.2%). The majority of patients, also, received anti-thrombotic medica-
tion (89.0%, 91.3% and 100% for rhythm control, rate control and non-pharmaco-
logical treatment, respectively). The most frequently performed diagnostic procedures 
across groups, on an annual basis, were INR monitoring (8.3–11.5 tests/year), echo-
cardiogram (4.0–4.4), liver (1.8–2.0) and renal function tests (1.7–1.9) and Holter 
monitoring (1.4–1.6). On average 4.3, 4.0 and 3.1 consultations/year with a cardiolo-
gist are necessary for the monitoring of patients on rhythm, rate control and non-
pharmacological treatment respectively. Annual hospitalization rates for patients 
under rhythm control were 20% due to AF recurrence, 13% due to cardiovascular 
complications and 5.63% due to drug adverse reactions. For patients under rate 
control, the corresponding percentages were 6%, 6.13% and 4% and for those under 
non-pharmacological therapy 18.75%, 3% and 4.86% respectively. CONCLUSIONS: 
Pharmacological rhythm control appears to be the prevailing initial AF treatment 
option in Greece. AF management requires an intense monitoring pattern, given that 
it can lead to increased frequency of hospitalizations.
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OBJECTIVES: To assess the incidence of venous thromboembolism (VTE) and current 
practice patterns for VTE prophylaxis in hospitalised acutely ill medical patients in 
Europe. METHODS: A systematic literature search was conducted in major databases 
on the epidemiology and treatment practices of VTE prevention among adult patients 
treated in hospital for major medical conditions. Relevant studies published between 
1999 and April 2010 were captured. RESULTS: Thirty-ﬁ ve multinational and coun-
try-speciﬁ c studies were retrieved, including randomized clinical trials, registry and 
chart audits, meta-analyses, and cross-sectional, retrospective, prospective, and obser-
vational studies. Among patients admitted for an acute medical illness, the incidence 
of VTE diagnosed during hospitalization ranged from 3.01% (mean hospital stay: 4.5 
days) to 15% (day 14 from index hospitalization). While clinical guidelines recom-
mend pharmacological VTE prophylaxis to all patients hospitalised for an acute 
medical illness who are bedridden, a clear identiﬁ cation of speciﬁ c risk groups who 
would beneﬁ t from VTE prevention is lacking. In the majority of studies captured, 
prophylaxis was underused among medical inpatients (all diseases); 33% to 82% of 
all patients hospitalised for acute medical illnesses did not receive any VTE prophy-
laxis. Furthermore, among patients who did receive prophylaxis, a considerable pro-
portion received medication that was not in agreement with guidelines, due to short 
duration, suboptimal dose, or inappropriate type of prophylaxis. Of all prescriptions, 
low molecular weight heparin was the most widely prescribed anticoagulant. In most 
cases, the duration of VTE prophylaxis did not exceed hospital stay duration, and 
varied between 5 and 33.8 days (mean duration). CONCLUSIONS: VTE imposes a 
substantial burden among hospitalised medical patients. Despite the proven efﬁ cacy 
of prophylaxis, utilization remains suboptimal among medical patients at risk for 
VTE, stressing the necessity for improved or easier access to proven preventive thera-
pies among these patients. 
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OBJECTIVES: Although the 6-minute walk test (sub-maximal exercise test) histori-
cally has been used to evaluate the effect of pharmacologic intervention in adults with 
pulmonary arterial hypertension (PAH), it was not widely regarded as appropriate for 
children at all ages. Thus, Peak VO2 (maximal exercise test) was used in a pediatric 
PAH trial (A1481131) to evaluate the effect of treatment. As this is the ﬁ rst large 
controlled trial using the Peak VO2 endpoint in this population, we investigated its 
performance in terms of correlational analyses. METHODS: Relationships between 
change in Peak VO2 and other endpoints were evaluated using correlation coefﬁ cients 
and regression analyses with the data from the 16-week randomized, placebo-con-
trolled, clinical trial of sildenaﬁ l assessing Peak VO2 at both baseline and week 16 in 
106 evaluable pediatric patients. a Bland-Altman plot was used to assess the reliability 
of screen and baseline visit data. RESULTS: The intraclass correlation was 0.79 for 
the screening and baseline visit Peak VO2 data. Additionally, agreement between these 
visits was supported by a Bland-Altman plot. Correlations of percentage changes in 
Peak VO2 from baseline with the change from baseline in the Physician Global Assess-
ment (overall and for sildenaﬁ l doses) and in World Health Organization Functional 
Class (WHO FC, with baseline of I and III/IV) correlated well (correlations of ≥0.40) 
and were responsive to change, while the low correlation with the Subject Global 
Assessment (0.12) suggested inﬂ uence by factors associated with child and parental 
proxy response and instrument administration. Percentage changes in Peak VO2 gave 
no real association (0.04) with the Family Cohesion of the Child Health Question-
naire. CONCLUSIONS: In pediatric PAH, Peak VO2 measurements exhibited good 
reliability. Improvements in Peak VO2 were shown to be associated with improve-
ments in qualitative clinical endpoints, including WHO FC and physician global 
assessment.
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OBJECTIVES: In comparative effectiveness research and economic evaluations, ben-
eﬁ ts of technologies are measured using multiple outcomes measures. Information 
lacks however about the importance of these endpoints for patients. We propose a 
new methodology to integrate patient weighted outcomes in a cost-efﬁ ciency frontier. 
We illustrate this methodology by means of an efﬁ ciency frontier analysis of ﬁ ve 
alternative treatments of patients with equinovarus deformity poststroke. METHODS: 
The Analytic Hierarchy Process (AHP) is a technique for multi-criteria analysis. The 
AHP supported 140 patients to prioritize the outcome measures of treatments of 
equinovarus deformity poststroke, and 10 professionals to prioritize the treatments 
regarding the outcome measures. These outcome measures include functional out-
comes, risk and side effects, comfort, daily effort, cosmetics, and impact of the treat-
ment. Sensitivity analysis is based on bootstrapping of the participants’ priorities. 
Relative costs include the device related costs and the care related costs of the treat-
ments. RESULTS: The overall effectiveness of soft-tissue surgery (.41) is ranked ﬁ rst, 
followed by orthopedic footwear (.18), ankle-foot orthosis (.15), surface electrostimu-
lation (.14), and ﬁ nally implanted electrostimulation (.12). Implanted electrostimula-
tion (.35) and soft-tissue surgery (.34) are considered to be most expensive, followed 
by surface electrostimulation (.26), orthopedic footwear (.03) and ankle-foot orthosis 
(.02). Based on these priorities of the treatments’ overall effectiveness and costs, an 
efﬁ ciency frontier was drawn that includes decision uncertainty. CONCLUSIONS: 
The results suggest that the cost-effectiveness of implanted electrostimulation and 
surface electrostimulation are unfavourable. This new methodology for efﬁ ciency 
frontier analysis allows decision makers to integrate the outcomes about the diverse 
values and costs of health care technology, and can be applied broadly. It is particu-
larly suitable in the ﬁ eld of early technology assessment, since the AHP supports a 
systematic estimation of priors about the effectiveness of alternative treatments.
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OBJECTIVES: We used the composite quality index (CompQualTM) to examine the 
association between venous thromboembolism (VTE) events and hospital quality for 
patients who underwent major orthopedic surgery.  METHODS: Using the empirical 
Bayes approach to combine mortality rates with information on hospital volume at each 
hospital, we created an index to weight observed mortality according to how reliable it 
is estimated, with remaining weight placed on hospital volume (CompQualTM scoring 
algorithm). Then, using a national database, all patients who underwent major ortho-
pedic surgery were identiﬁ ed. Rates for patients who had a VTE event during their initial 
hospitalization were calculated. By using the algorithm, every provider in the Medicare 
data set was ranked according to their quality. Multivariate regression was used to see 
the effect of quality on VTE event rates. RESULTS: We obtained a sample that included 
2,745 patients in the VTE group. After controlling for patients’ demographic and 
clinical factors, VTE events in low quality hospitals were almost 2.5 times higher than 
VTE events in high quality hospitals (p = 0.000). We also compared the ranking with 
only volume and only for hospitals. Our combined measure to rank the hospital was 
more effective and explained more variation than the individual measures (pseudo 
R-square: 0.46 for composite score, 0.15 for volume only, 0.09 for mortality only). 
CONCLUSIONS: Using national Medicare data for patients with VTE, we found that 
a simple composite measure was a strong predictor of subsequent performance for 
operations. In this regard, it was more effective than individual measures. Such mea-
sures would be useful to help patients and payers identify low quality hospitals for 
major surgery. Any policy implementation that would decrease the variation in hos-
pital quality would have a direct effect on the rates of VTE events.
